11,072 Shares in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Purchased by Virtu Financial LLC

Virtu Financial LLC purchased a new stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 11,072 shares of the biotechnology company’s stock, valued at approximately $332,000.

Other large investors also recently made changes to their positions in the company. Annandale Capital LLC acquired a new stake in shares of Rocket Pharmaceuticals during the third quarter worth $66,000. Tower Research Capital LLC TRC raised its holdings in Rocket Pharmaceuticals by 105.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,557 shares of the biotechnology company’s stock worth $107,000 after buying an additional 1,829 shares during the period. Old Well Partners LLC acquired a new stake in Rocket Pharmaceuticals during the 4th quarter worth about $200,000. Capstone Investment Advisors LLC purchased a new stake in Rocket Pharmaceuticals during the fourth quarter valued at about $217,000. Finally, Amalgamated Bank boosted its holdings in shares of Rocket Pharmaceuticals by 5.4% in the fourth quarter. Amalgamated Bank now owns 8,653 shares of the biotechnology company’s stock worth $259,000 after buying an additional 440 shares during the period. Institutional investors own 98.39% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on RCKT. William Blair restated an “outperform” rating on shares of Rocket Pharmaceuticals in a research report on Monday, June 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, February 27th. Needham & Company LLC reiterated a “buy” rating and set a $53.00 price target on shares of Rocket Pharmaceuticals in a report on Tuesday, May 7th. The Goldman Sachs Group assumed coverage on Rocket Pharmaceuticals in a research note on Tuesday, April 2nd. They issued a “neutral” rating and a $39.00 price objective for the company. Finally, UBS Group lowered their target price on Rocket Pharmaceuticals from $56.00 to $54.00 and set a “buy” rating on the stock in a research note on Friday, March 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $52.13.

Insider Activity at Rocket Pharmaceuticals

In other Rocket Pharmaceuticals news, Director David P. Southwell sold 70,000 shares of the firm’s stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $24.36, for a total transaction of $1,705,200.00. Following the transaction, the director now directly owns 95,160 shares in the company, valued at $2,318,097.60. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Rocket Pharmaceuticals news, Director David P. Southwell sold 70,000 shares of the stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $24.36, for a total transaction of $1,705,200.00. Following the transaction, the director now owns 95,160 shares in the company, valued at $2,318,097.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David P. Southwell sold 10,000 shares of the business’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $24.05, for a total transaction of $240,500.00. Following the completion of the sale, the director now owns 114,784 shares of the company’s stock, valued at $2,760,555.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 105,282 shares of company stock valued at $2,551,801. Insiders own 31.10% of the company’s stock.

Rocket Pharmaceuticals Stock Up 0.8 %

RCKT opened at $20.85 on Friday. The company has a market capitalization of $1.89 billion, a PE ratio of -7.26 and a beta of 1.08. The business has a 50-day moving average of $22.54 and a 200-day moving average of $26.12. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $14.89 and a fifty-two week high of $32.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.47 and a quick ratio of 10.47.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.01. During the same quarter last year, the firm earned ($0.73) earnings per share. Equities research analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.85 EPS for the current fiscal year.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.